-
-
-
-
-
-
-
BTIG Reiterates Buy Rating on Arvinas Inc. (ARVN)
-
-
-
-
-
-
-
Arvinas, Inc. (ARVN) Misses Q4 EPS by 59c
-
-
-
-
-
-
-
Arvinas Inc. (ARVN) PT Raised to $14 at BTIG
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Arvinas Inc. (ARVN)
-
-
-
-
-
-
-
FDA accepts Arvinas drug application for advanced breast cancer treatment
-
-
-
-
-
-
-
Leerink Partners Downgrades Arvinas Inc. (ARVN) to Market Perform
-
-
-
-
-
-
-
TD Cowen Downgrades Arvinas Inc. (ARVN) to Hold
-
428,039 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

